(Editors’ Note: As discussed below, TPRP is a very illiquid security).
Tower Properties (OTCPK:TPRP) is one of the cheapest companies I have been able to find and is almost completely undiscovered by the investing public. This is a company where you are getting $1 worth of real estate, cash, shares, and property management/development/construction management earning streams for about $0.35. It is run by an excellent management team that works smart and hard to grow shareholder value over time.
Tower properties is primarily a real estate ownership company. From their home page, Tower Properties owns and/or manages a portfolio of approximately 3.5 million square feet of commercial and industrial properties, including over 1,600 multi-family units in the Kansas City and St. Louis metropolitan areas. In addition, Tower has developed over one and one-half million square feet of various types of property. That is a lot of real estate for a company that has a Market Capitalization of only $61 million ($14,500 price x 4,201 shares).
Top Cheap Stocks To Buy Right Now: Valspar Corporation (The)(VAL)
- [By Ben Levisohn]
Chilton first bought Sherwin Williamsduring the depths of the Great Recession. Why? “Paint is a good business,” he says. “There are 134 million homes in the US. I like knowing that when I got to bed at night…there paint will be peeling.” And while Sherwin Williamshas had quite a run, there’s a good reason to buy now: Its acquisition of Valspar (VAL).
- [By Ben Levisohn]
UBS analyst John Roberts and team consider whether Sherwin-Williams’ (SHW) pending purchase of Valspar (VAL) is a sign of peak pain in the U.S.:
Top Cheap Stocks To Buy Right Now: Bank of Hawaii Corporation(BOH)
- [By Monica Gerson]
Bank of Hawaii Corporation (NYSE: BOH) is expected to report its quarterly earnings at $0.99 per share on revenue of $149.88 million.
Zions Bancorporation (NASDAQ: ZION) is projected to post its quarterly earnings at $0.39 per share on revenue of $576.49 million.
Top Cheap Stocks To Buy Right Now: Seres Therapeutics, Inc.(MCRB)
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
- [By Lisa Levin]
Seres Therapeutics Inc (NASDAQ: MCRB) shares dropped 70 percent to $10.69 after the company reported interim results from SER-109 Phase 2 ECOSPOR study in multiply recurrent clostridium difficile infection. The study did not achieve primary endpoint.
- [By Lisa Levin]
Seres Therapeutics Inc (NASDAQ: MCRB) shares shot up 35 percent to $12.51. Seres Therapeutics reported initiation of new SER-019 study announced FY16 loss of $2.30 per share on revenue of $21.766 million.